Loading stock data…
MBX Biosciences (MBX)
$53.85+1.54 (+2.94%)
Market ClosedLast close Jun 29
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MBX Biosciences, Inc. in the Healthcare sector is trading at $53.85 with a market capitalization of $1.9B. Wall Street consensus targets $69.09 (11 analysts), implying a +28.3% move over the next 12 months. The stock is currently near its 52-week high of $55.00, remaining 81.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +28.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$27.27M↓ | -$25.80M↓ | -$23.93M↓ | -$21.80M↑ | -$26.53M |
| Net Income | -$23.52M↓ | -$22.06M↓ | -$21.62M↓ | -$19.41M↑ | -$23.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109),...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-19.78%
Volume
Today's trading volume
1.05M
Recent News
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?
MBX Biosciences recently reported full 12-week Phase 2 Avail trial results and one-year open-label extension data for once-weekly canvuparatide in adults with chronic hypoparathyroidism, showing higher responder rates versus placebo, sustained calcium control, kidney function improvements, and a generally well tolerated safety profile. An interesting angle for investors is the pharmacokinetic profile, with low peak-to-trough variability supporting convenient once-weekly dosing as the company...
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)
MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 19.
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run
MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.
Insider Stock Buying Reaches US$1.06m On MBX Biosciences
Multiple insiders secured a larger position in MBX Biosciences, Inc. ( NASDAQ:MBX ) shares over the last 12 months...